Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines

Q: What is the clinical evidence from this study?

Study design: Review. Population: Atrial fibrillation in older adults with frailty, disability, and polypharmacy. Intervention: Anticoagulation management (DOACs vs. VKAs) and multidisciplinary geriatric stratification.

Q: What does this research mean for the field?

Accurate clinical stratification distinguishing frailty from disability is essential before applying the 2024 ESC guideline recommendation to maintain vitamin K antagonist therapy over switching to direct oral anticoagulants in older adults with atrial fibrillation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Crescenzo Testa; Marco Salvi; Irene Zucchini; Chiara Cattabiani; Francesco Giallauria; Laura Petraglia; Dario Leosco; Fulvio Lauretani; Marcello Maggio

doi:10.3390/ijerph22020179

January 28, 2025International Journal of Environmental Research and Public HealthOpen Access

Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines

View Full Paper

Ask AI

Bookmark

Share

Key result

Distinguishing frailty from disability should guide VKA-to-DOAC switching decisions in older adults with AF.

Figures

Why the study?

The 2024 ESC guidelines introduced a recommendation to maintain vitamin K antagonists over switching to DOACs in clinically stable elderly AF patients, prompting exploration of its implications and the need to distinguish frailty from disability.

How should clinicians stratify frailty versus disability and manage oral anticoagulation (VKA maintenance vs. switching to DOAC) in elderly patients with atrial fibrillation under the 2024 ESC guidelines?

Key Points

To examine the geriatric implications of the 2024 European Society of Cardiology guidelines for atrial fibrillation, emphasizing the necessity of distinguishing frailty from disability.
Clinical review and geriatric perspective evaluating the European Society of Cardiology 2024 guidelines for managing atrial fibrillation in older adults.
Analysis of clinical stratification models, including the 9-point Clinical Frailty Scale, and evidence on anticoagulant regimens in aging populations.
Frailty reflects depleted physiological reserves while preserving functional independence, whereas disability involves functional impairment; conflating the two risks therapeutic inertia or inappropriate over-treatment.
Guidelines recommend maintaining stable vitamin K antagonist therapy rather than routinely switching to direct oral anticoagulants in clinically stable elderly patients with atrial fibrillation.
A meta-analysis of over one million patients reveals frailty prevalence reaches approximately 40% in atrial fibrillation, supporting comprehensive geriatric assessments and multidisciplinary care models.

Structured PICO

How should clinicians stratify frailty versus disability and manage oral anticoagulation (VKA maintenance vs. switching to DOAC) in elderly patients with atrial fibrillation under the 2024 ESC guidelines?

P

Population

Older adults (particularly aged ≥75 years) with atrial fibrillation, comorbidities, polypharmacy, frailty, or disability.

I

Intervention

Direct oral anticoagulants (DOACs, such as apixaban, edoxaban, rivaroxaban, dabigatran) and multidisciplinary care (AF-CARE framework integrating cardiology and geriatrics, using validated frailty tools like the Clinical Frailty Scale and Comprehensive Geriatric Assessment).

C

Comparator

Continuation of vitamin K antagonist (VKA, e.g., warfarin) therapy or standard single-specialty care without formal distinction between frailty and disability.

This geriatric perspective critiques the 2024 ESC atrial fibrillation guideline recommendation on maintaining VKA therapy in patients ≥75 years, highlighting that conflating disability with frailty in the underlying FRAIL-AF trial risks inappropriate therapeutic inertia against DOACs in truly frail but autonomous older adults.

Limitations

The 2024 ESC Class IIb recommendation to continue VKA in patients aged ≥75 years is derived from a single trial (FRAIL-AF) that conflated frailty with severe disability using the Groningen Frailty Indicator.
Up to 87% of older adults hospitalized with atrial fibrillation or heart failure are excluded from major clinical trials due to stringent inclusion criteria.
Simplified frailty indices in clinical trials often omit key geriatric domains such as cognitive function, polypharmacy, and fall risk.
Evidence supporting the 2024 ESC guideline recommendation to maintain VKA over switching to a DOAC in clinically stable patients aged ≥75 years is limited to a single open-label RCT (FRAIL-AF) that misclassified disabled patients as frail.
Major cardiovascular trials systematically exclude up to 87% of hospitalized older adults with AF or heart failure due to age, comorbidity, and functional criteria, limiting generalizability.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinicians should differentiate frailty from disability before deferring DOACs in older AF; leaves open uniform applicability of 2024 ESC guidance.

Abstract

Atrial Fibrillation can be considered a geriatric syndrome for its prevalence and incidence, its impact on patients' quality of life, and Health Systems' economy. The European Society of Cardiology 2024 guidelines introduce a recommendation for maintaining vitamin K antagonist therapy over switching to direct oral anticoagulants in clinically stable elderly patients with atrial fibrillation. This article explores the implications of this indication for the geriatric clinical context. The focus will also be devoted to the need for the stratification of older patients with atrial fibrillation, making an appropriate distinction between frailty and disability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Testa et al. (2025) conducted a review in Atrial fibrillation in older adults with frailty, disability, and polypharmacy. Anticoagulation management (DOACs vs. VKAs) and multidisciplinary geriatric stratification was evaluated. Accurate stratification distinguishing frailty from disability is essential before applying the 2024 ESC recommendation to maintain VKA over switching to DOACs in older adults with AF.

synapsesocial.com/papers/6a747e94fc5fd65369f53daf https://doi.org/10.3390/ijerph22020179

View Full Paper

Ask AI

Bookmark

Share

Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading